The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Apnimed Secures $150M Financing to Launch Oral Sleep Apnea Treatment

Key Facts

1Apnimed entered into a senior secured credit facility for up to $150 million with HealthCare Royalty Partners (HCRx).

2The financing will support commercial readiness and the planned U.S. launch of AD109, an oral pill for Obstructive Sleep Apnea (OSA).

3The company is on track to submit a New Drug Application (NDA) for AD109 later this quarter.

Create Free Account

Apnimed, Inc. has announced a senior secured credit facility for up to $150 million with HealthCare Royalty Partners (HCRx). This strategic financing is designed to support the commercial readiness and planned U.S. launch of AD109, a novel oral therapy for Obstructive Sleep Apnea (OSA). The company remains on track to submit its New Drug Application (NDA) for AD109 to the FDA later this quarter. By securing this capital, Apnimed strengthens its balance sheet as it transitions from a clinical-stage biotech to a commercial entity. This move significantly reduces liquidity risks and provides the necessary resources for a robust market entry. The funding highlights investor confidence in the potential of AD109 to disrupt the traditional sleep apnea treatment market.